Tag Archives: Abilify

Of Persistence and Ethics in Phase III

Persistence paid off for Lundbeck and Takeda, whose first Phase III program for their antidepressant Lu AA21004 failed. With revised dosing, they ran another extensive set of pivotal trials, have announced that they will be filing for regulatory approval in … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , , , , , | 1 Comment